NorthWest Biotherapeutics Inc (NWBO): L's Plll rGBM didn't even divide up into...

Reply Private New

Replies (2) Next 10 Prev Next

learningcurve2020

Send PM Follow Ignore

Followers	45
Posts	15382
Boards Moderated	0
Alias Born	09/16/2012

learningcurve2020

Re: flipper44 post# 683647

Saturday, 04/06/2024 2:40:09 PM

Saturday, April 06, 2024 2:40:09 PM

L's Plll rGBM didn't even divide up into two groups.

>>This study aims to assess the effectiveness of the re-irradiation and bevacizumab combination in treating second-progression GBM patients who are resistant to bevacizumab monotherapy. This retrospective study enrolled 64 patients who developed a second progression after single-agent bevacizumab therapy. The patients were divided into two groups: 35 underwent best supportive care (none-ReRT group), and 29 received bevacizumab and re-irradiation (ReRT group). The study measured the overall survival time after bevacizumab failure (OST-BF) and re-irradiation (OST-RT). Statistical tests were used to compare categorical variables, evaluate the difference in recurrence patterns between the two groups, and identify optimal cutoff points for re-irradiation volume. The results of the Kaplan–Meier survival analysis indicated that the re-irradiation (ReRT) group experienced a significantly higher survival rate and longer median survival time than the non-ReRT group.

https://www.nature.com/articles/s41598-023-36290-2